COVID-19-mRNA Vaccine (Stemirna Therapeutics)

mRNA新型冠状病毒肺炎疫苗（斯微生物）

Report date: 2026/05/13 15:37:27

Base Information

Drug NameCOVID-19-mRNA Vaccine (Stemirna Therapeutics)
Drug Alias Name新型冠状病毒mRNA疫苗SW-BIC-213斯维尔克SW-BIC-213
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryLao People's Democratic RepublicMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesStemirna Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Oriental HospitalStemirna Therapeutics
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A